Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 2/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | CDC14B | O60729 | 1/20 | 0.30 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.30 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23155220 | 0.95 | ALOX5 (0.41) | ALOX5GGPS1AHRPRKDCPTGES2 | |
| SCHEMBL23155365 | 0.94 | ALOX5 (0.41) | ALOX5GGPS1AHRPRKDC | |
| SCHEMBL23155171 | 0.93 | ALOX5 (0.41) | ALOX5GGPS1AHRPRKDCPTGES2 | |
| SCHEMBL21141143 | 0.93 | ALOX5 (0.44) | ALOX5GGPS1AHRPRKDCPTGES2 | |
| SCHEMBL21141142 | 0.93 | ALOX5 (0.44) | ALOX5GGPS1AHRPRKDCPTGES2 | |
| SCHEMBL23155230 | 0.91 | ALOX5 (0.39) | ALOX5GGPS1AHRPRKDCPTGES2 | |
| SCHEMBL23155318 | 0.90 | ALOX5 (0.39) | ALOX5GGPS1AHRPRKDCPTGES2 | |
| SCHEMBL23313945 | 0.90 | ALOX5 (0.45) | ALOX5GGPS1PRKDCPTGES2PLA2G2A | |
| SCHEMBL23313696 | 0.90 | ALOX5 (0.45) | ALOX5GGPS1PRKDCPTGES2PLA2G2A | |
| SCHEMBL16683997 | 0.88 | ALOX5 (0.41) | ALOX5GGPS1PRKDCPTGES2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11594684-B2 | Condensed-cyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-02-28 | — | — | US | disclosed |
| US-20210098700-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11594684-B2 | Condensed-cyclic compound and organic light emitting device including the same | CRY1, SMCHD1, CXCR1 | ALOX5 2879/4885GGPS1 1660/4885AHR 1479/4885 |
| US-20210098700-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | CRY1, SMCHD1, CXCR1 | ALOX5 2879/4885GGPS1 1660/4885AHR 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.